CHICAGO, IL / ACCESSWIRE / September 26, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment…
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA")…
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult…
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE,…
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 25, 2023 / The U.S. Department of Health and Human Services (HHS)…
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver,…
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per shareSAN…
PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…